This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2005;293:2079-2081.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Boston—Although anti-HIV drug regimens have had a profound impact on preventing mother-to-child transmission of HIV, researchers have been grappling with the potential health consequences of a treatment strategy commonly used in resource-poor countries for that purpose. Findings presented here at the 12th Annual Retrovirus Conference provide new evidence regarding some potential risks of this regimen—which consisted of a single dose of nevirapine during labor to the mother and a single dose to the newborn during the first 3 days after delivery—as well as some early evidence showing potential benefits from alternative regimens.

Single-dose nevirapine for mothers and their newborn infants has been a cornerstone for reducing mother-to-child transmission in developing countries from about 30% to 13% or less. The regimen is "the little engine that could," the strategy that provided the momentum to start programs for preventing vertical transmission in developing countries, where it has been . . . [Full Text of this Article]

DRUG RESISTANCE CONCERNS



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?